CLINICAL RESEARCH: ACUTE CORONARY SYNDROMES
Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation
William S. Weintraub, MD, FACC*,*,
Elizabeth M. Mahoney, ScD ,
Andre Lamy, MD ,
Steven Culler, PhD*,
Yong Yuan, PhD ,
Jaime Caro, MD||,
Sylvie Gabriel, MD¶,
Salim Yusuf, MD, FACC CURE Study Investigators
* Emory University, Atlanta, Georgia
New England Research Institutes, Watertown, Massachusetts
McMaster University, Hamilton, Ontario, Canada
Bristol-Myers Squibb, Princeton, New Jersey
|| Caro Research Institute, Concord, Massachusetts
¶ Sanofi-Synthelabo, Paris, France
Manuscript received July 26, 2004;
revised manuscript received November 13, 2004,
accepted November 16, 2004.
* Reprint requests and correspondence: Dr. William S. Weintraub, Emory Center for Outcomes Research, 1256 Briarcliff Road, Suite 1N, Atlanta, Georgia 30306
(Email: wweintr{at}emory.edu).
OBJECTIVES: We sought to evaluate the long-term cost-effectiveness of clopidogrel for up to one year after an acute coronary syndrome (ACS) without ST-segment elevation.
BACKGROUND: The efficacy of platelet inhibition with clopidogrel for up to one year after ACS was demonstrated in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial, a randomized trial of 12,562 patients in 28 countries that was conducted between 1998 and 2000. Patients were given clopidogrel (300-mg load followed by 75 mg/day) versus placebo, both in addition to aspirin, for a mean of nine months.
METHODS: We used patient-level clinical outcomes and resource use from the CURE trial and estimates of life expectancy gains as a result of the prevention of the clinical events of death, stroke, and myocardial infarction on the basis of data from external sources.
RESULTS: Excluding clopidogrel costs, average costs of hospitalizations alone were $325 less for the clopidogrel arm (95% confidence interval $722 to $45) using diagnosis-related group-based Medicare reimbursement rates. When including clopidogrel costs ($766 greater for the clopidogrel arm), average total costs were $442 higher for the clopidogrel arm (95% confidence interval $62 to $820). The incremental cost-effectiveness ratio (ICER) on the basis of the Framingham Heart Study was $6,318 per life-year gained (LYG) with clopidogrel, with 94% of bootstrap-derived ICER estimates <$50,000/LYG; based on Saskatchewan, the ICER was $6,475/LYG with 98% of estimates <$50,000.
CONCLUSIONS: Platelet inhibition with clopidogrel in patients for up to one year after presentation with an acute coronary syndrome is both effective and cost-effective.
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | CURE = Clopidogrel in Unstable angina to prevent Recurrent Events trial | | DRG = diagnosis-related group | | ICER = incremental cost-effectiveness ratio | | MI = myocardial infarction | | LOS = length of stay | | LYG = life-year gained | | PCI = percutaneous coronary intervention | | QALYs = quality-adjusted life-years |
|
This article has been cited by other articles:

|
 |

|
 |
 
G. A. Diamond and S. Kaul
Cost, Effectiveness, and Cost-Effectiveness
Circ Cardiovasc Qual Outcomes,
January 1, 2009;
2(1):
49 - 54.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Cohen and M. R. Reynolds
Interpreting the results of cost-effectiveness studies.
J. Am. Coll. Cardiol.,
December 16, 2008;
52(25):
2119 - 2126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Goldman and J.-M. Gaspoz
Cost-Effectiveness of Clopidogrel: Seeing through the Smoke
Med Decis Making,
November 1, 2008;
28(6):
803 - 809.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Mahoney, K. Wang, D. J. Cohen, A. T. Hirsch, M. J. Alberts, K. Eagle, F. Mosse, J. D. Jackson, P. G. Steg, D. L. Bhatt, et al.
One-Year Costs in Patients With a History of or at Risk for Atherothrombosis in the United States
Circ Cardiovasc Qual Outcomes,
September 1, 2008;
1(1):
38 - 45.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. S. Weintraub
Pharmacoeconomic Concepts in Antiplatelet Therapy: Understanding Cost-Effectiveness Analyses Using Clopidogrel as an Example
Journal of Cardiovascular Pharmacology and Therapeutics,
June 1, 2008;
13(2):
107 - 119.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. B. Matchar and D. B. Mark
Strategies for Incorporating Resource Allocation and Economic Considerations: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
132S - 140S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Harrington, R. C. Becker, C. P. Cannon, D. Gutterman, A. M. Lincoff, J. J. Popma, G. Steg, G. H. Guyatt, and S. G. Goodman
Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
670S - 707S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. C. Becker, T. W. Meade, P. B. Berger, M. Ezekowitz, C. M. O'Connor, D. A. Vorchheimer, G. H. Guyatt, D. B. Mark, and R. A. Harrington
The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
776S - 814S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. M. Krumholz
The Year in Epidemiology, Health Services, and Outcomes Research
J. Am. Coll. Cardiol.,
October 4, 2005;
46(7):
1362 - 1370.
[Full Text]
[PDF]
|
 |
|
|